News Release

Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma

Peer-Reviewed Publication

Impact Journals LLC

Figure 1

image: 

B) Transaxial CT and PET slices at the lung metastasis level in the left lung on the left. Maximum intensity projection (MIP)-PET whole body images on the right. The upper row shows images in April 2018 when there was no evidence of metabolic active disease. The lower row images in January 2020 demonstrate a relapse in the left lung, which is seen transaxial images and as a tiny spot in the MIP-image.

view more 

Credit: 2023 Gouda et al.

“Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma.”

BUFFALO, NY- January 12, 2024 – A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.”

Pazopanib, a multi-kinase VEGF inhibitor, is currently FDA approved for advanced renal cell carcinoma and advanced soft tissue sarcoma; but limited evidence exists on its efficacy in bone sarcomas.

In this case report, researchers Mohamed A. Gouda, Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, and Vivek Subbiah from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. The report also reviews the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.

“In brief, this case, in accordance with previously reported evidence, provides proof of activity of pazopanib in EWSR1-NFATC2 positive sarcoma. The report shows that pazopanib when administered in an adjuvant capacity demonstrated its effectiveness in preventing or delaying the progression of additional metastasis. Nevertheless, due to the adjuvant nature of the treatment, it remains uncertain whether this approach would have resulted in tumor shrinkage. Further pre-clinical studies and clinical studies using pazopanib in EWSR1-NFATC2 sarcomas are warranted.”

 

Read the full paper: DOI: https://doi.org/10.18632/oncoscience.587 

Correspondence to: Vivek Subbiah

Email: vivek.subbiah@scri.com 

Keywords: pazopanib, precision oncology, sarcoma
 

About Oncoscience

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:

 

For media inquiries, please contact media@impactjournals.com.

 

Oncoscience Journal Office

6666 East Quaker Str., Suite 1D

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 4

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.